189 related articles for article (PubMed ID: 20975079)
1. Inhibition of DNA synthesis in mouse epidermis by topical imiquimod is dependent on opioid receptors.
McLaughlin PJ; Rogosnitzky M; Zagon IS
Exp Biol Med (Maywood); 2010 Nov; 235(11):1292-9. PubMed ID: 20975079
[TBL] [Abstract][Full Text] [Related]
2. Modulation of the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: novel therapies for squamous cell carcinoma of the head and neck.
McLaughlin PJ; Stucki JK; Zagon IS
Head Neck; 2012 Apr; 34(4):513-9. PubMed ID: 21584896
[TBL] [Abstract][Full Text] [Related]
3. T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases.
Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
Immunobiology; 2011 May; 216(5):579-90. PubMed ID: 20965606
[TBL] [Abstract][Full Text] [Related]
4. Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model.
Donahue RN; McLaughlin PJ; Zagon IS
Exp Biol Med (Maywood); 2011 Sep; 236(9):1036-50. PubMed ID: 21807817
[TBL] [Abstract][Full Text] [Related]
5. Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer.
Zagon IS; Donahue R; McLaughlin PJ
Exp Biol Med (Maywood); 2013 May; 238(5):579-87. PubMed ID: 23856908
[TBL] [Abstract][Full Text] [Related]
6. B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases.
Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
Immunobiology; 2011; 216(1-2):173-83. PubMed ID: 20598772
[TBL] [Abstract][Full Text] [Related]
7. Astrocyte proliferation is regulated by the OGF-OGFr axis in vitro and in experimental autoimmune encephalomyelitis.
Campbell AM; Zagon IS; McLaughlin PJ
Brain Res Bull; 2013 Jan; 90():43-51. PubMed ID: 22985690
[TBL] [Abstract][Full Text] [Related]
8. Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function.
Zagon IS; Donahue RN; Rogosnitzky M; McLaughlin PJ
Exp Biol Med (Maywood); 2008 Aug; 233(8):968-79. PubMed ID: 18480416
[TBL] [Abstract][Full Text] [Related]
9. Mutations in the opioid growth factor receptor in human cancers alter receptor function.
Kren NP; Zagon IS; McLaughlin PJ
Int J Mol Med; 2015 Jul; 36(1):289-93. PubMed ID: 26005722
[TBL] [Abstract][Full Text] [Related]
10. Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis.
Donahue RN; McLaughlin PJ; Zagon IS
Am J Physiol Regul Integr Comp Physiol; 2009 Jun; 296(6):R1716-25. PubMed ID: 19297547
[TBL] [Abstract][Full Text] [Related]
11. The opioid growth factor-opioid growth factor receptor axis: homeostatic regulator of cell proliferation and its implications for health and disease.
McLaughlin PJ; Zagon IS
Biochem Pharmacol; 2012 Sep; 84(6):746-55. PubMed ID: 22687282
[TBL] [Abstract][Full Text] [Related]
12. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice.
Donahue RN; McLaughlin PJ; Zagon IS
Gynecol Oncol; 2011 Aug; 122(2):382-8. PubMed ID: 21531450
[TBL] [Abstract][Full Text] [Related]
13. Featured Article: Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis.
Ludwig MD; Zagon IS; McLaughlin PJ
Exp Biol Med (Maywood); 2018 Feb; 243(4):361-369. PubMed ID: 29307283
[TBL] [Abstract][Full Text] [Related]
14. Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin.
Donahue RN; McLaughlin PJ; Zagon IS
Exp Biol Med (Maywood); 2011 Jul; 236(7):883-95. PubMed ID: 21685240
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer cells.
Zagon IS; Verderame MF; Hankins J; McLaughlin PJ
Int J Oncol; 2007 Apr; 30(4):775-83. PubMed ID: 17332915
[TBL] [Abstract][Full Text] [Related]
16. Opioid growth factor - opioid growth factor receptor axis inhibits proliferation of triple negative breast cancer.
Zagon IS; Porterfield NK; McLaughlin PJ
Exp Biol Med (Maywood); 2013 Jun; 238(6):589-99. PubMed ID: 23918871
[TBL] [Abstract][Full Text] [Related]
17. Selective blockade of the OGF-OGFr pathway by naltrexone accelerates fibroblast proliferation and wound healing.
Immonen JA; Zagon IS; McLaughlin PJ
Exp Biol Med (Maywood); 2014 Oct; 239(10):1300-9. PubMed ID: 25030485
[TBL] [Abstract][Full Text] [Related]
18. Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers.
Zagon IS; Donahue RN; McLaughlin PJ
Am J Physiol Regul Integr Comp Physiol; 2009 Oct; 297(4):R1154-61. PubMed ID: 19675283
[TBL] [Abstract][Full Text] [Related]
19. The opioid growth factor, [Met5]-enkephalin, inhibits DNA synthesis during recornification of mouse tail skin.
Wilson RP; McLaughlin PJ; Lang CM; Zagon IS
Cell Prolif; 2000 Apr; 33(2):63-73. PubMed ID: 10845251
[TBL] [Abstract][Full Text] [Related]
20. The opioid growth factor, [Met5]-enkephalin, and the zeta opioid receptor are present in human and mouse skin and tonically act to inhibit DNA synthesis in the epidermis.
Zagon IS; Wu Y; McLaughlin PJ
J Invest Dermatol; 1996 Mar; 106(3):490-7. PubMed ID: 8648182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
